nach oben

Journal of Neural Transmission

Erschienen in:

01.02.2016 | Neurology and Preclinical Neurological Studies - Review Article

Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression

verfasst von: Makoto Naoi, Peter Riederer, Wakako Maruyama

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Monoamine oxidase types A and B (MAO-A, MAO-B) regulate the levels of monoamine neurotransmitters in the brain, and their dysfunction may be involved in the pathogenesis and influence the clinical phenotypes of neuropsychiatric disorders. Reversible MAO-A inhibitors, such as moclobemide and befloxatone, are currently employed in the treatment of emotional disorders by inhibiting the enzymatic degradation of dopamine, serotonin and norepinephrine in the central nervous system (CNS). It has been suggested that the irreversible MAO-B inhibitors selegiline and rasagiline exert a neuroprotective effect in Parkinson’s and Alzheimer’s diseases. This effect, however, is not related to their inhibition of MAO activity; in animal and cellular models, selegiline and rasagiline protect neuronal cells through their anti-apoptotic activity and induction of pro-survival genes. There is increasing evidence that MAO-A activity, but not that of MAO-B, is implicated in the pathophysiology of neurodegenerative disorders, but also in gene induction by MAO-B inhibitors; on the other hand, selegiline and rasagiline increase MAO-A mRNA, protein, and enzyme activity levels. Taken together, these results suggest that each MAO subtype exerts effects that modulate the expression and activity of the other isoenzyme. The roles of MAO-A and -B in the CNS should therefore be re-evaluated with respect to the “type-specificity” of their inhibitors, which may not be unconditional during chronic treatment. Mao-a expression, in particular, may be implicated in pathogenesis and phenotypes in neuropsychiatric disorders. MAO-A expression is modified by mao polymorphisms affecting its transcriptional efficiency, as well as by mutations and polymorphism of parkin, Sirt1, FOXO, microRNA, presenilin-1, and other regulatory proteins. In addition, childhood maltreatment has been shown to have an impact upon adolescent social behavior in children with mao-a polymorphisms of low transcriptional activity. Low MAO-A activity may increase the levels of serotonin and norepinephrine, resulting in disturbed neurotransmitter system development and behavior. This review discusses genetic and environmental factors involved in the regulation of MAO-A expression, in the contexts of neuropsychiatric function and of the regulation of neuronal survival and death.

Ahlskog JE, Uitti RJ (2010) Rasagiline, Parkinson neuroprotection, and delayed-start trial. Still no satisfaction? Neurology 74(14):1143–1148PubMedCentralPubMedCrossRef

Akao Y, Maruyama W, Shimizu S, Yi H, Shamoto-Nagai M et al (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and its inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82(4):913–923PubMedCrossRef

Alia-Klein N, Goldstein RZ, Kriplani A, Logan J, Tomasi D et al (2008) Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28(19):5099–5104PubMedCentralPubMedCrossRef

Alves E, Summavielle T, Alves CJ, Gomes-da-Silva J, Barata JC et al (2007) Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescence rat brain mitochondria. J Neurosci 27(38):10203–10210PubMedCrossRef

Barac YD, Bar-Am O, Liani E, Amit T, Frolov L et al (2012) I₁ imidazoline receptor: novel potential cytoprotective target of TV1022, the S-enantiomer of rasagiline. PLoS ONE 7(11):e47980CrossRef

Bartl J, Müller T, Grünblatt E, Gerlach M, Riederer P (2014) Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 121(4):379–383PubMedCrossRef

Binda C, Hubalek F, Li M, Herzig Y, Sterling J et al (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48(26):8148–8154PubMedCentralPubMedCrossRef

Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease; a long-term study. J Neural Transm 64(2):113–127PubMedCrossRef

Black GC, Chen ZY, Craig JW, Powell JF (1991) Dinucleotide repeat polymorphism at the MAOA locus. Nucleic Acids Res 19(3):689PubMedCentralPubMed

Bortolato M, Shih JC (2011) Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol 100:13–42PubMedCentralPubMedCrossRef

Bortolato M, Chen K, Shih JC (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 60(13–14):1527–1533PubMedCentralPubMedCrossRef

Brandon NJ, Miller JK, Korth C, Sive H, Singh KK, Sawa A (2009) Understanding the role of DISC1 in psychiatric disease and during normal development. J Neurosci 29(4):12768–12775PubMedCrossRef

Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA (1993a) Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262(5133):578–580PubMedCrossRef

Brunner HG, Nelen MR, van Zandvoort P, Abeling NG, van Gennip AH et al (1993b) X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 52(6):1032–1039PubMedCentralPubMed

Buneeva OA, Medvedeva MV, Medvedev AE (1999) Incorporation of ubiquitin into rat brain mitochondria is accompanied by increased proteolytic digestibility of MAO. Neurobiology (Bp) 7(3):257–261

Cao X, Wei Z, Gabriel GG, Li X, Mousseau DD (2007) Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal culture: implications for Alzheimer disease-related pathology. BMC Neurosci 8:73PubMedCentralPubMedCrossRef

Cao X, Li X-M, Mousseau DD (2009a) Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signal pathways. Life Sci 85(5–6):262–268PubMedCrossRef

Cao X, Rui L, Pennington PR, Chlan-Fourney J, Jiang Z et al (2009b) Serine 209 resides with a putative p38(MAPK) consensus motif and regulates monoamine-oxidase-A activity. J Neurochem 111(1):101–110PubMedCrossRef

Casarejos MJ, Solano RM, Menendez J, Rodriguez-Navarro JA, Correa C et al (2005) Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J Neurochem 94(4):1005–1014PubMedCrossRef

Caspi A, McClay J, Moffitt TE, Mill J, Martin J et al (2002) Role of genotype in the cycle of violence in maltreated children. Science 297(5582):851–854PubMedCrossRef

Chaitidis P, Billett E, Kuban RJ, Ungethuem U, Kuhn H (2005) Expression regulation of MAO isoforms in monocytic cells in response to TH2 cytokines. Med Sci Monit 11(8):BR259–BR265PubMed

Chaudhuri AD, Yelamanchili AV, Fox HS (2013) MicroRNA-142 reduces monoamine oxidase A expression and activity in neuronal cells by downregulating SIRT1. PLoS ONE 8(11):e79579PubMedCrossRef

Chen K, Ou XM, Chen G, Choi SH, Shih JC (2005) R1, a novel repressor of the human monoamine oxidase A. J Biol Chem 280(12):11552–11559PubMedCentralPubMedCrossRef

Chen K, Ou X-M, Wu JB, Shih JC (2011) Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol Pharmacol 79(2):308–317PubMedCentralPubMedCrossRef

Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F et al (2003) A new formation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110(11):1241–1255PubMedCrossRef

Cohen IL, Liu X, Lewis ME, Chudley A, Forster-Gibson C et al (2011) Autism severity is associated with child and maternal MAOA genotypes. Clin Genet 79(4):355–362PubMedCrossRef

Collins GG, Sandler M, Williams ED, Youdim MB (1970a) Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225(5235):817–820PubMedCrossRef

Collins GG, Pryse-Davies J, Sandler M, Southgate J (1970b) Effects of pretreatment with oestradiol, progesterone and DOPA on monoamine oxidase activity in rat. Nature 226(5246):642–643PubMedCrossRef

Cookson MR, Bandmann O (2010) Parkinson’s disease: insights from pathways. Human Mol Genetics 19(Review 1):R21–R27CrossRef

Damier P, Kastner A, Agid Y, Hirsch EC (1996) Does monoamine oxidase B play a role in dopaminergic nerve cell death in Parkinson’s disease? Neurology 46(5):1262–1269PubMedCrossRef

De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98(11):6168–6173PubMedCentralPubMedCrossRef

Deckert J, Catalano M, Syagailo VY, Bosi M, Okladnova O et al (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorders. Human Mol Genet 8(4):621–624CrossRef

Donmez G, Outeiro TF (2013) Sirt1 and Sirt2: emerging targets in neurodegeneration. EMBO Mol Med 5(3):344–352PubMedCentralPubMedCrossRef

Ducci F, Enoch A-A, Hodgkinson C, Xu K, Caterna M et al (2008) Interaction between a functional MAOA locus and childhood sexual abuse predicts alcoholism and antisocial personality disorder in adult women. Mol Psychiatry 13(3):334–347PubMedCrossRef

Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S et al (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7(11):1513–1529PubMedCrossRef

Edmondson DE, Binda C, Mattevi A (2007) Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys 464(2):269–276PubMedCentralPubMedCrossRef

Edwards AC, Dodge KA, Laterndresse SJ, Landsford JE, Bates JE et al (2010) MAOA uVNTR and early physical discipline interact to influence delinquent behavior. J Child Psychol Psychiatry 51(6):679–687PubMedCentralPubMedCrossRef

Egashira T, Sakai K, Sakurai M, Takayama F (2003) Calcium disodium edetate enhances type A monoamine oxidase activity in monkey brain. Biol Trace Elem Res 94(3):203–211PubMedCrossRef

Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a “non-MAO” macromolecular target for L-deprenyl?: studies on MAOB mutant mice. Life Sci 63(12):181–186CrossRef

Falk EM, Cook VJ, Nichols DE, Sprague JE (2002) An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 72(3):617–622PubMedCrossRef

Fang J, Yu PH (1994) Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33(6):763–768PubMedCrossRef

Felner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28(7):995–1002PubMedCrossRef

Fergusson DM, Boden JM, Horwood LJ, Miller AL, Kennedy MA (2011) MAOA abuse exposure and antisocial behavior: 30-year longitudinal study. Brit J Psych 198(6):457–463CrossRef

Finberg JP (2010) Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson’s disease with neuroprotective potential. Rambam Maimonides Med J 1(1):e0003PubMedCentralPubMedCrossRef

Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billet EE (2007) Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem 103(6):2189–2199PubMedCrossRef

Fitzgerald JC, Ugun-Klusek A, Allen G, De Girolamo LA, Hargreaves I et al (2014) Monoamine oxidase-A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins. FASEB J 28(1):218–229PubMedCrossRef

Fornai F, Chen K, Giorgi FS, Gesi M, Alessandri MG, Shih JC (1999) Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J Neurochem 73(6):2434–2440PubMedCrossRef

Fornai F, Glorgi FS, Gesi M, Chen K, Alessri MG, Shih JC (2001) Biochemical effects of the monoamine neurotoxin DSP-4 and MDMA in specific brain regions of MAO-B deficient mice. Synapse 39(3):213–221PubMedCrossRef

Fowler JS, Logan J, Ding YS, Franceschi D, Wang GJ et al (2001) Non-MAO A binding of clorgyline in white matter in human brain. J Neurochem 79(5):1039–1046PubMedCrossRef

Gan L, Mucke L (2008) Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58(11):1–14

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L et al (2012) Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119(1):39–52PubMedCentralPubMedCrossRef

Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265(5589):80–81PubMedCrossRef

Götz ME, Breithaupt W, Sautter J, Kupsch A, Schwarz J et al (1997) Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidase A and B in the brain of the common marmoset. J Neural Transm [Suppl] 52:277–284

Green AR, Mitchell BD, Tordoff AF, Youdim MBH (1977) Evidence for dopamine deamination by both type A and B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60(3):343–349PubMedCentralPubMedCrossRef

Grimbsby J, Chen K, Wang LJ, Lan NC, Shih JC (1991) Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Acad Sci USA 88(9):3637–3641CrossRef

Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L et al (1997) Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 17(2):206–210PubMedCrossRef

Grunewald M, Johnson S, Lu D, Wang Z, Lomberk G et al (2012) Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. J Biol Chem 287(29):24195–24206PubMedCentralPubMedCrossRef

Guo G, Ou XM, Roettger M, Shih JC (2008) The VNTR 2 repeat in MAOA and delinquent behavior in adolescence and young adulthood: associations of MAOA promoter activity. Eur J Hum Genet 16(5):622–634CrossRef

Gyárfás T, Knuutila J, Lindolm P, Rantamäki T, Castrén E (2010) Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol 30(3):361–369PubMedCrossRef

Hebert SS, De Strooper B (2007) miRNAs in neurodegeneration. Science 317(5842):1179–1180PubMedCrossRef

Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine inhibitors. Nature 311(5985):467–469PubMedCrossRef

Hernan MA, Chechoway H, O’Brien R, Costa-Mallen P, De Vivo I et al (2002) MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 58(9):1381–1387PubMedCrossRef

Hill J, Breen G, Quinn J, Tibu F, Sharp H, Pickles A (2013) Evidence for interplay between genes and maternal stress in utero: monoamine oxidase A polymorphism moderates effects of life events during pregnancy on infant negative emotionality at 5 weeks. Genes Brain Behav 12(3):388–396PubMedCrossRef

Hinds HL, Hendricks RW, Craig JW, Chen ZY (1992) Characterization of a highly polymorphic region near the first exon of the human MAOA gene containing a GT dinucleotide and a novel VNTR motif. Genomics 13(3):896–897PubMedCrossRef

Holschneider DP, Scremin OU, Huynh L, Chen K, Shih JC (1999) Lack of protection from ischemic injury of monoamine oxidase B-deficient mice following middle cerebral artery occlusion. Neurosci Lett 259(3):161–164PubMedCrossRef

Holt A, Berry MD, Boulton AA (2004) On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neuro Toxicol 25(1–2):251–266

Houtkooper RH, Pirien E, Auwerx J (2012) Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13(4):225–238PubMedCrossRef

Huang Y-Y, Cate SP, Battistuzzi C, Oquendo MA, Brent D, Mann JJ (2004) An association between a functional polymorphism in the monoamine oxidase A gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 29(8):1498–1505PubMedCrossRef

Hubalek F, Binda C, Ki M, Herzig Y, Sterling J et al (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47(7):1760–1768PubMedCrossRef

Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M (2012) Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J Neural Transm 119(4):405–414PubMedCrossRef

Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M (2013) Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J Neural Transm 120(3):435–444PubMedCrossRef

Inaba-Hasegawa K, Maruyama W, Naoi M (2015) Phenylethylamine a substrate of type B monoamine oxidase induces type A isoenzyme in human SH-SY5Y cells, but serotonin, a MAO-A inhibitor, does not (in preparation)

International Parkinson Disease Genomic Consortium (2011) Imputation of sequence variations for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377(9766):64–69

Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C et al (2003) Parkin gene inactivation alters behavioral and dopamine neurotransmission in the mouse. Hum Mol Gen 12(18):2277–2291PubMedCrossRef

Itzhak Y, Stein I, Zhang S-H, Kassim CO, Cristante D (1991) Binding of σ-ligands to C57BL/6 mouse brain membranes: Effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of σ-receptor subtypes. J Pharm Exper Ther 257(1):141–148

Jahng W, Houpt TA, Joh TH, Son JH (1998) Differential expression of monoamine oxidase A, serotonin transporter, tyrosine hydroxylase and norepinephrine transporter mRNA by anorexia and food deprivation. Brain Res Devel Brain Res 107(2):241–246CrossRef

Jakubauskiene E, Janaviciute V, Peciuliene I, Söderkvist P, Kanopka A (2012) G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease. FEBS Lett 586(20):3698–3704PubMedCrossRef

Jiang S, Xin R, Lin S, Qian Y, Tang G, Wang D, Wu X (2001) Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. Am J Med Genet 105(8):783–788PubMedCrossRef

Jiang H, Jiang Q, Liu W, Feng J (2006) Parkin suppresses the expression of monoamine oxidases. J Biol Chem 281(13):8591–8599PubMedCrossRef

Johnson S, Stockmeier CA, Meyer JH, Austin MC, Albert PR et al (2011) The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology 36(10):2139–2148PubMedCentralPubMedCrossRef

Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17(7):30–36CrossRef

Kabayama M, Sakoori K, Yamada K, Ornthanali VG, Ota M et al (2013) Rines E3 ubiquitin ligase regulates MAO-A levels and emotional responses. J Neurosci 33(32):12940–12953PubMedCrossRef

Kim J, Inoue K, Ishii J, Vanti WB, Voronov S et al (2007) A microRNA feedback circuit in midbrain dopamine neurons. Science 317(5842):1220–1224PubMedCentralPubMedCrossRef

Kinnally EL, Huang YY, Haverly R, Burke AK, Galfalvy H et al (2009) Parental care moderates the influence of MAO-A-UVNTR genotype and childhood stressors on trait impulsivity and aggression in adult women. Psychiatr Genet 19(3):126–133PubMedCentralPubMedCrossRef

Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T et al (2010) SIRT1 gene is associated with major depressive disorder in the Japanese population. J Affect Disord 26(1–2):167–173CrossRef

Konradi C, Riederer P, Youdim MB (1966) Hydrogen peroxide enhances the activity of monoamine oxidase type B but not of type A: a pilot study. J Neural Transm Suppl 22:61–73

Krysiak JM, Kreuzer J, Macheroux P, Hermetter A, Sieber SA, Breinbauer R (2012) Activity-based probes for studying the activity of flavin-dependent oxidases and the protein target profiling of monoamine oxidase inhibitors. Angew Chem Int Ed 51(28):7035–7040CrossRef

Lam EWF, Francis RE, Petkovic M (2006) FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 34(5):722–726PubMedCrossRef

Lamensdorf I, Youdim MB, Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67(4):1532–1539PubMedCrossRef

Lee AK, Mojtahed-Jaberi M, Kyriakou T, Astarloa EAO, Arno M et al (2010) Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus. Nutrition 26(4):411–422PubMedCentralPubMedCrossRef

Levant B, Morgan KA, Ahlgren-Beckendorf JA, Grandy DK, Chen K et al (2001) Modulation of [³H]quinopirole binding at striatal D2 dopamine receptor by a monoamine-A-like site: evidence from radioligand studies and D2-receptor- and MAO(A)-deficient mice. Life Sci 70(2):229–241PubMedCrossRef

Libert S, Pointer K, Bell EL, Das A, Cohen DE et al (2011) SIRT1 Activates MAO-A in the brain to mediate anxiety and exploratory drive. Cell 147(7):1459–1472PubMedCentralPubMedCrossRef

Lim LC, Powell J, Murray R, Gill M (1994) Monoamine oxidase A gene and bipolar affective disorders. Am J Hum Genet 54(6):1122–1124PubMedCentralPubMed

Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL et al (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci 28(51):13805–13814PubMedCrossRef

Lyles GA (1978) Effects of L-DOPA administration upon monoamine oxidase activity in rat tissues. Life Sci 22(7):603–609PubMedCrossRef

Magyar K (2011) Pharmacology of selegiline. Int Rev Neurobiol 100:65–84PubMedCrossRef

Malmberg K, Wargelius HL, Licherstein P, Oreland L, Larsson JO (2008) ADHD and disruptive behavior scores-association with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents. BMC Psychiatry 8:28PubMedCentralPubMedCrossRef

Márquez C, Poirier GL, Cordero M, Larsen MH, Groner A et al (2012) Peripuberty stress leads to abnormal aggression, altered amygdala and orbitofrontal reactivity and increased prefrontal MAOA gene expression. Transl Psychiatry 3:e216CrossRef

Maruyama W, Naoi M (2013) “70^th Birthday Professor Riederer” Induction of glial cell-line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy? J Neural Transm 120(1):83–89PubMedCrossRef

Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78(4):727–735PubMedCrossRef

Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y et al (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44(6):293–400CrossRef

May T (1993) 1-Methyl-4-phenylpyridinium (MPP⁺) binds with high affinity to a β-carboline binding site localized on monoamine oxidase type A in rat brain. Neurosci Lett 162(1–2):55–58PubMedCrossRef

Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D et al (2006) Elevated monoamine oxidase A levels in the brain. An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63(11):1209–1216PubMedCrossRef

Meza-Sosa KF, Pedraza-Alva G, Pérez-Martinez L (2014) microRNAs: key triggers of neuronal cell fate. Front Cell Neurosci 8:175PubMedCentralPubMedCrossRef

Miller JR, Edmondson DE (1999) Structure-activity relationship in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 38(41):13670–13683PubMedCrossRef

Morishima M, Harada N, Hara S, Sano H, Takahasi A et al (2006) Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats. Neuropsychopharmacology 31(12):2627–2638PubMedCrossRef

Muninos-Gemeno M, Espinosa-Parrilla Y, Guidi M, Kagerbauer B, Sipilä T et al (2010) Human microRNAs, miR-22, miR-138-2, miR-148a, and miR-488are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol Psychiatry 69(6):526–533CrossRef

Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio R et al (1990) Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem 54(1):242–247PubMedCrossRef

Nandigama RK, Edmondson DE (2000) Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 39(49):15258–15265PubMedCrossRef

Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceut Design 16(25):2799–2817CrossRef

Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka T (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading cell death or neuroprotection. J Neural Transm Suppl 71:67–77PubMedCrossRef

Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y (2011) Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int Rev Neurobiol 100:85–106PubMedCrossRef

Naoi M, Maruyama W, Inaba-Hasegawa K (2013a) Revelation in neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 13(6):671–684PubMedCrossRef

Naoi M, Maruyama W, Yi H (2013b) Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J Neural Transm 120(11):1539–1551PubMedCrossRef

Nedic G, Pivac N, Hercigonja DK, Jovancevic M, Curkovic KD, Muck-Seler D (2010) Platelet monoamine oxidase activity in children with attention-deficit/hyperactivity disorder. Psychiatry Res 175(3):252–255PubMedCrossRef

Nelson RJ, Trainor BC (2007) Neuronal mechanisms of aggression. Nat Rev Neurosci 8(7):536–546PubMedCrossRef

Nishimura AL, Guindalini C, Oliveira JR, Nitrini R, Bahia VS et al (2005) Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late-onset Alzheimer’s disease? J Mol Neurosci 27:213–217PubMedCrossRef

Noorbakhsh F, Ramachandran R, Barsby N, Ellestad KK, LeBlanc A et al (2010) MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. FASEB J 24(6):1799–1812PubMedCrossRef

Oreland L (2004) Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neuro Toxicol 25(1–2):79–89

Ou XM, Chen K, Shih JC (2004) Dual functions of transcription factors, transforming growth factor-β-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. J Biol Chem 279(20):21021–21028PubMedCrossRef

Ou XM, Chen K, Shih JC (2006a) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103(29):10923–10928PubMedCentralPubMedCrossRef

Ou XM, Chen K, Shih JC (2006b) Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 281(30):21512–21525PubMedCrossRef

Ou XM, Lu D, Johnson C, Chen K, Youdim MB et al (2009) Glyceraldehyde-3-phosphate-monoamine oxidase B-mediated cell death by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res 16(2):148–159PubMedCentralPubMedCrossRef

Ou XM, Johnson C, Lu D, Johnson S, Paul IA et al (2011) Ethanol increases TIEG2–MAO B cell death cascade in the prefrontal cortex of ethanol-preferring rats. Neurotox Res 19(4):511–518PubMedCentralPubMedCrossRef

Ozaita A, Olmos G, Boronat MA, Lizcano JM, Mercedes Unzeta JMM et al (1997) Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I₂-imidazoline receptors in rat liver. Br J Pharm 121(5):901–912CrossRef

Park YU, Jeong J, Lee H, Mun JY, Kim JH et al (2010) Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. Proc Natl Acad Sci USA 107(41):17785–17790PubMedCentralPubMedCrossRef

Pennington PR, Wei Z, Rui L, Dig JA, Graham B et al (2011) Alzheimer disease-related presenilin-1 variants exert distinct effects on monoamine oxidase-A activity in vitro. J Neural Transm 118(7):987–995PubMedCrossRef

Philibert RA, Wernett P, Plume J, Packer H, Brody GH, Beach RH (2011) Gene environmental interactions with a novel variable Monoamine oxidase A transcriptional enhancer are associated with antisocial personality disorder. Biol Psychol 87(3):366–371PubMedCentralPubMedCrossRef

Pinsonneault JK, Papp AC, Sadee W (2006) Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) n human brain: dissection of epigenetic and genetic factors. Hum Mol Gen 15(17):2636–2649PubMedCrossRef

Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C, Bompart G, Parini A (2003) Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am J Physiol Renal Physiol 284(1):F167–F174PubMedCrossRef

Raddatz R, Parini A, Lanier SM (1995) Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase-B. J Biol Chem 270(46):27961–27968PubMedCrossRef

Ren Y, Jiang H, Ma D, Nakaso K, Feng J (2011) Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum Mol Gen 20(6):1074–1083PubMedCentralPubMedCrossRef

Riederer P, Lachenmayer L (2003) Selegiline’s neuroprotective capacity revisited. J Neural Transm 110(11):1273–1278PubMedCrossRef

Riederer P, Konradi C, Habenstreit G, Youdim MBH (1989) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 126(1):41–45CrossRef

Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11(13):2033–2043PubMedCrossRef

Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Chavez M, Paz F et al (2004) Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression then their non-mutation carrier kin. J Neurol Neurosurg Psychiatry 75(3):500–502PubMedCentralPubMedCrossRef

Rivera M, Gutiérrez B, Molina E, Torres-González F, Bellón JA et al (2009) High-activity variants of the MAOA polymorphism increase the risk for depression in a large primary care sample. Am J Med Gent B Neuropsychiatry Genet 150B(3):395–402CrossRef

Roberts RC (2007) Disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophrenia Bull 33(1):11–15CrossRef

Sabol SZ, Hu S, Hamer D (1998) A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103(3):273–279PubMedCrossRef

Salichon N, Gaspar P, Upton AL, Picaud S, Hanoun N et al (2001) Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J Neurosci 21(3):884–896PubMed

Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautography with ³H-Ro 41-I 049 and ³H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12(5):1977–1999PubMed

Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K et al (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70(3):755–774PubMedCrossRef

Schmid T, Krüger M, Braun T (2007) NSCL-1 and -2 control the formation of precerebellar nuclei by orchestrating the migration of neuronal precursor cells. J Neurochem 102(6):2061–2072PubMedCrossRef

Schreiber SN, Knutti D, Brogli K, Uhlmann T, Kralli A (2003) The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor (ERR). J Boil Chem 278(11):9013–9018CrossRef

Scott AL, Bortolato M, Chen K, Shih JC (2008) Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. NeuroReport 19(7):739–743PubMedCentralPubMedCrossRef

Shekim WO, Bylund DB, Alexson J, Gaser RD, Jones SB et al (1986) Platelet MAO and measures of attention and impulsivity in boys with attention deficient disorder and hyperactivity. Psychiatry Res 18(2):179–188PubMedCrossRef

Shih JC, Thompson RF (1999) Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 65(3):593–598PubMedCentralPubMedCrossRef

Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197–217PubMedCentralPubMedCrossRef

Shih JC, Boyang J, Chen K (2011) Transcriptional regulation and multiple functions of MAO genes. J Neural Transm 118(7):979–986PubMedCentralPubMedCrossRef

Shimazu S, Katsuki H, Akaike A (1999) Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-d-aspartate toxicity. Eur J Pharmacol 377(1):29–34PubMedCrossRef

Siddiqui A, Hanson I, Anderson JK (2012) MAO-B elevation decreases parkins’s ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Rad Res 46(8):1011–1018CrossRef

Sims KB, de la Chapelle A, Norio R, Sankila EM, Hsu YP et al (1989) Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2(1):1069–1076PubMedCrossRef

Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D (2008) Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 312(1–2):131–138PubMedCrossRef

Sprague JE, Nichols DE (1995) The monoamine oxidase inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficient. J Pharmacol Exp Ther 273(2):667–673PubMed

Sun Y, Zhang J, Yuan Y, Yu X, Shen Y, Xu Q (2012) Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population. Am J Med Genet Part B 159B:104–111PubMedCrossRef

Takahashi M, Tanaka S, Masliah E, Ueda K (2002) Association of monoamine oxidase A gene polymorphism with Alzheimer’s disease and Lewy body variant. Neurosci Lett 327(1):79–82CrossRef

Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 55(4):533–538PubMedCrossRef

Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB et al (2000) Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm Suppl 60:77–100PubMed

Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW et al (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301(2):753–764PubMedCrossRef

Tiihoren J, Rautiainen M-R, Ollila HM, Repo-Tiihonen E, Virkkunen M et al (2014) Genetic background of extreme violent behavior. Mol Psychiatry. doi:10.1038/mp.2014.130

Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ et al (2013) Distribution of monoamine oxidase proteins in human. J Cereb Blood Flow Metab 33(6):863–871PubMedCentralPubMedCrossRef

Udemgba C, Johnson S, Stockmeier CA, Luo J, Albert PR et al (2014) The expression of KLF11 (TIEG2), a monoamine oxidase B transcriptional activator in the prefrontal cortex of human alcohol dependence. Alcohol Clin Exper Res 38(1):144–151CrossRef

Wadia JS, Chalmers-Redman RME, Ju WJH, Garlile GW, Phillips JL et al (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (−)-deprenyl. J Neurosci 18(3):932–947PubMed

Wang CC, Borchert A, Ugun-Klusek A, Tang LY, Lui WT et al (2011) Monoamine oxidase A expression is vital for embryonic brain development by modulating developmental apoptosis. J Biol Chem 286(32):28322–28330PubMedCentralPubMedCrossRef

Wei Q, Yeung M, Jurma OP, Andersen JK (1996) Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP. J Neurosci Res 46(6):666–673PubMedCrossRef

Wei Z, Gabriel GG, Rui L, Cao X, Pennington PR et al (2012) Monoamine oxidase-A physically interacts with presenilin-1 (M146V) in the mouse cortex. J Alzheimers Dis 28(20):403–422PubMed

Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MBH (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053:348–355PubMedCrossRef

Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MBH (2009) Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat brain. J Neural Transm 116(11):1456–1472CrossRef

Widom CS, Brzustowicz LM (2006) MAOA and the “cycle of violence”: childhood abuse and neglect, MAOA genotype, and risk for violent and antisocial behavior. Biol Psychiatry 60(7):684–689PubMedCrossRef

Willy P, Murray IR, Qian J, Busch BB, Stevens WC Jr et al (2004) Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand. Proc Natl Acad Sci USA 101(24):8912–8917PubMedCentralPubMedCrossRef

Winblad B, Gottfries CG, Oreland L, Wiberg A (1979) Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol 57(2):129–132PubMed

Wu JB, Shih JC (2011) Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol Pharmacol 80(4):714–723PubMedCentralPubMedCrossRef

Wu YH, Fischer DF, Swaab DF (2007) A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer’s disease patients. Brain Res 1167:13–19PubMedCrossRef

Xu Q, Jia YB, Zhang BY (2004) Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry 9(5):510–521PubMedCrossRef

Yelamanchili SV, Chaudhuri AD, Chen L-N, Xiong H, Fo HS (2010) MicroRNA-21 dysregulates the expression of MEF2Cin neurons in monkey and human SIV/HIV neurological disease. Cell Death Disease 1:e77PubMedCentralPubMedCrossRef

Yi H, Akao Y, Maruyama W, Chen K, Shih, Naoi M (2006) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96(2):541–549PubMedCrossRef

Youdim MBH, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 147(Suppl 1):S287–S296PubMedCentralPubMed

Youdim MBH, Tipton KF (2002) Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotype and Parkinson’s disease. Parkinsonism Relat Disord 8(4):247–253PubMedCrossRef

Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309PubMedCrossRef

Yu PH, Davis BA, Fang J, Boulton AA (1994) Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63(5):1820–1828PubMedCrossRef

Zhang Z, Chen K, Shih JC, Teng CT (2006) Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors. Mol Endocrinol 20(7):1547–1561PubMedCrossRef

Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I (2010) Role of presenilins in neuronal calcium homeostasis. J Neurosci 30(25):8566–8580PubMedCentralPubMedCrossRef

Zhu QS, Chen K, Shih JC (1994) Bidirectional promoter of human monoamine oxidase A (MAO-A) controlled by transcriptional factor Sp1. J Neurosci 14(12):7393–7403PubMed

Titel: Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression
verfasst von: Makoto Naoi
Peter Riederer
Wakako Maruyama
Publikationsdatum: 01.02.2016
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1362-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Mitochondria: old and new target in brain research

Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: a brief overview

Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease

Mitochondrial mechanisms of redox cycling agents implicated in Parkinson’s disease